Posted in | News | Nanoanalysis

Researchers Evaluate NanoString’s Breast Cancer Intrinsic Subtyping Assay

A developer of molecular diagnostics and provider of life science tools for translational research, NanoString Technologies, has announced the initiation of the first study which will be followed by further studies to assess the clinical application of its breast cancer intrinsic subtyping assay which is solely based on the PAM50 gene signature.

The nCounter analysis system of NanoString

The primary investigation will use TransATAC study samples to test the capability of the assay to measure the possibility of cancer reoccurrence in women undergoing post-menopause having hormone receptor-positive, early stage breast cancer (ESBC) after undergoing hormonal therapy.

The translational study group, TransATAC has utilized the data and tissue from Arimidex, Tamoxifen, Alone or as a Combination (ATAC) trial to analyze the molecular characteristics of cancer cells in ESBC patients. The PAM50 gene signature offers a subtype classification called intrinsic subtyping which is based on the fundamental history of a person’s breast tumor. This intrinsic subtyping can be utilized to obtain a prognostic score.

The medical developmental program for breast cancer intrinsic subtyping assay was designed in order to support its integration into breast cancer therapeutic procedures and clinical regulatory clearance.

After receiving regulatory approvals, NanoString desires to make available, its Breast Cancer Intrinsic Subtyping assay on the nCounter platform to global medical centers and pathology laboratories. The nCounter is a completely automated digital counting and detection analysis system with an extremely simple process-flow. All the consumables and reagents needed to perform the experiment are present in the assay kits. Its capability to test small samples and its adaptability with different types of samples such as paraffin-embedded, formalin-fixed tissue enables the system to be applicable for analyzing several problems arising in translational medicine. Apart from gene expression assays, the company offers assays for miRNA analysis and copy number variation. At present, the nCounter system is available only for research purposes.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). Researchers Evaluate NanoString’s Breast Cancer Intrinsic Subtyping Assay. AZoNano. Retrieved on November 22, 2024 from https://www.azonano.com/news.aspx?newsID=23171.

  • MLA

    Chai, Cameron. "Researchers Evaluate NanoString’s Breast Cancer Intrinsic Subtyping Assay". AZoNano. 22 November 2024. <https://www.azonano.com/news.aspx?newsID=23171>.

  • Chicago

    Chai, Cameron. "Researchers Evaluate NanoString’s Breast Cancer Intrinsic Subtyping Assay". AZoNano. https://www.azonano.com/news.aspx?newsID=23171. (accessed November 22, 2024).

  • Harvard

    Chai, Cameron. 2019. Researchers Evaluate NanoString’s Breast Cancer Intrinsic Subtyping Assay. AZoNano, viewed 22 November 2024, https://www.azonano.com/news.aspx?newsID=23171.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.